Frontlight ResearchEarly access
Active, not recruitingNo phase
Optimization of NIBS for Diabetic Neuropathy Neuropathic Pain
Key facts
- Who runs it
- Case Western Reserve University
- Where
- Chicago and Cleveland, United StatesSee the 2 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 60 people, planned
- Started
- 6 Jun 2019
- Expected to end
- 7 May 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Active Comparator: Active tDCS + Active TUS
- Sham
- Record updated
- 29 June 2026
Who can take part
- Age
- 40 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Able to provide informed consent to participate in the study
- Subjects between 40 to 80 years old
- Having diabetic neuropathic pain, involving at least 1 foot, with existing pain for at least 6 months, and having pain on at least half the days in the past 6 months with an average of at least a 4 on a 0-10 VAS scale)
- Having pain resistant to common analgesics and medications for first-line therapy of chronic pain such as Tylenol, Aspirin, Ibuprofen, Soma, Parafon Forte DCS, Zanaflex, Codeine, etc
- Must have the ability to feel pain as self-reported
Who cannot take part
- Contraindications to tDCS in conjunction with TUS, i.e. metallic implant in the brain or implanted brain medical devices
- History of alcohol or drug abuse within the past 6 months as self-reported
- History of neurological disorders as self-reported
- History of unexplained fainting spells as self-reported
- History of severe head injury resulting in more than a momentary loss of consciousness as self-reported
- History of neurosurgery as self-reported
- Subject is pregnant
- Use of carbamazepine within the past 6 months as self-reported
- Suffering from severe depression (with a PHQ 9 score of ≥ 10)
- Unstable pain (defined as pain intensities that vary by more than 4 points on 0-10 VAS scale over the 1-week period of trial run-in)
Where in United States
- Ciro Ramos EstebanezChicago, United States
- University Hospitals Cleveland Medical Center/ Dahms Clinical Research UnitCleveland, United States
About the trial
What the trial wants to find out
The purpose of this study is to assess the effects of Transcranial Direct Current Stimulation (tDCS) in combination with Transcranial ultrasound (TUS) for the treatment of pain and functional limitations in subjects with Diabetic Neuropathic Pain.
The 2 groups in the trial
- Active Comparator: Active tDCS + Active TUSExisting treatment, for comparison
Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
- ShamSham treatment, for comparison
Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Optimization of Non-Invasive Brain Stimulation for Diabetic Neuropathy
- Record updated
- 29 June 2026